AMGNHealthcare · Drug Manufacturers - GeneralThe 34 Wall Street analysts covering Amgen, Inc. hold a median 12-month price target of $405 — -10.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 27 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Amgen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Issuance (46): The company has been issuing shares or taking on financing, diluting existing holders.
Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on AMGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −10.4% from it.
Of the 20 most recent actions, 7 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | Oppenheimer | Maintains | Outperform | $450 → $480 |
| 21 Oct 2026 | Barclays | Maintains | Equal-Weight | $380 → $400 |
| 13 Oct 2026 | Guggenheim | Maintains | Neutral | $388 → $378 |
| 13 Oct 2026 | Guggenheim | Maintains | Neutral | — |
| 12 Oct 2026 | BMO Capital | Maintains | Market Perform | — |
| 12 Oct 2026 | BMO Capital | Maintains | Market Perform | $450 → $415 |
| 12 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $435 → $430 |
| 12 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 Oct 2026 | UBS | Maintains | Buy | $430 → $470 |
| 9 Oct 2026 | UBS | Maintains | Buy | — |
| 8 Oct 2026 | Cantor Fitzgerald | Maintains | Neutral | — |
| 8 Oct 2026 | Cantor Fitzgerald | Maintains | Neutral | $400 → $440 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $400 → $430 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 7 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | $362 → $359 |
| 7 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 Oct 2026 | Truist Securities | Maintains | Hold | $362 → $380 |
| 7 Oct 2026 | Truist Securities | Maintains | Hold | — |
| 29 Sept 2026 | Scotiabank | Maintains | Sector Outperform | — |
| 29 Sept 2026 | Scotiabank | Maintains | Sector Outperform | $450 → $500 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AMGN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Amgen, Inc. returned +59.1% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 28% of US stocks
Cheaper than 20% of US stocks
Cheaper than 5% of US stocks
Cheaper than 20% of US stocks
Higher than 52% of US stocks
Higher than 79% of US stocks
Higher than 84% of US stocks
Higher than 90% of US stocks
Higher than 84% of US stocks
Higher than 96% of US stocks
Higher than 90% of US stocks
Higher than 81% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Amgen, Inc. has a market value of $242.2B and an enterprise value of $285.5B.
Revenue in the twelve months to 30 June 2026: $38.1B. The latest quarter grew 9.5% year on year.
Net income over the same four quarters: $8.7B, a 23.0% net margin.
Diluted earnings per share, trailing twelve months: $16.09.
Free cash flow in the twelve months to 30 June 2026: $10.2B.
Amgen, Inc. spent $5.3B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 27.8×; forward P/E: 18.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.23%, paying out 61% of earnings.
Amgen, Inc. employs 31,500 people — $1.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Amgen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Amgen announced it will report third-quarter 2026 financial results on Tuesday, November 3, 2026, after the close of U.S. financial markets.
Why it matters — AMGN watchers may note the scheduled date and timing for the company’s quarterly results announcement.
Amgen heads into Q3 earnings after beating expectations for four consecutive quarters. Biosimilar competition, pricing pressure and higher costs may challenge growth.
Why it matters — AMGN watchers may focus on whether drug sales can offset these potential headwinds in the Q3 results.
Amgen announced plans to present new data across its rare and other serious autoimmune disease portfolio at ACR Convergence 2026. The highlights include Phase 3 OASIZ-301 results for dazodalibep in Sjögren’s disease, long-term UPLIZNA data in IgG4-related disease, and real-world evidence for KRYSTEXXA and TAVNEOS.
Why it matters — The planned presentations will provide updates on several Amgen therapies and programs in rare and serious autoimmune diseases.
Amgen generated more revenue than Vertex Pharmaceuticals in every observed quarter across roughly the last eight quarters. Amgen's revenue fluctuated moderately quarter to quarter, while Vertex's rose steadily and gradually.
Why it matters — The comparison highlights Amgen's larger revenue base alongside its greater quarter-to-quarter variation, relevant context for AMGN watchers.
A Zacks Investment Research preview says Amgen is scheduled to report next week and that Wall Street expects earnings growth. It also says the company lacks the two key ingredients associated with a likely earnings beat.
Why it matters — AMGN watchers may follow the upcoming report and the expectations described in the preview.
The 34 Wall Street analysts covering Amgen, Inc. have a median 12-month price target of $405, with estimates ranging from $225 to $500. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 34 analysts covering Amgen, Inc., 12 rate it a Buy, 17 a Hold and 5 a Sell. Ticker Nerd's systematic factor model ranks Amgen, Inc. 94 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Amgen, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 34 analysts implies -10.4% from the last close, and Ticker Nerd's factor model ranks Amgen, Inc. 94 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Amgen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $225 to $500 over the next 12 months.
Amgen, Inc. returned +59.1% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Amgen Inc. Common Stock represents ownership in Amgen Inc., a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases.
The most recent item we track (PRNewsWire, 28 Oct 2026): "AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS". Amgen announced it will report third-quarter 2026 financial results on Tuesday, November 3, 2026, after the close of U.S. financial markets.
Amgen Inc. Common Stock represents ownership in Amgen Inc., a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases. The company’s portfolio spans therapies used in oncology, inflammation, cardiovascular conditions, osteoporosis, and rare diseases, making it a significant participant in global biopharmaceutical markets. Amgen also supports its business through biologic manufacturing capabilities and a commercial organization that brings prescription medicines to patients and healthcare providers in multiple regions. As a large-cap healthcare equity, Amgen Inc. Common Stock is widely followed by market participants for its role in the biotechnology sector and its exposure to branded medicines, biologics, and specialty treatment areas.
CEO Mr. Robert A. Bradway · 31,500 employees · United States · https://www.amgen.com
